| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Advisory Board
|
|
IFC
|
|
|
|
Contents
|
|
v
|
|
| Introduction |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview
The Alliance for Aging Research leads a coalition of not-for-profit organizations representing the interests of patients, caregivers, health advocates, and older Americans that aim to advance the deve...
|
John C. Morris,
Dennis J. Selkoe
|
S1-S3
|
|
| Biofluids |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CSF biomarkers for Alzheimer's disease: current utility and potential future use
Abstract: Over the past 15 years, cerebrospinal fluid (CSF) biomarkers have been shown to be useful for both the diagnosis as well as the prognosis in Alzheimer's disease. It has been shown the CSF le...
|
David M. Holtzman
|
S4-S9
|
|
|
|
Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants
Abstract: Identifying a biomarker for Alzheimer's disease that can be obtained from a blood sample has been a goal of researchers for many years. Over the past few years a number of investigators have...
|
Richard Mayeux,
Nicole Schupf
|
S10-S19
|
|
| Imaging |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia
Abstract: Since the introduction of amyloid imaging nearly 10 years ago, this technique has gained widespread use and acceptance. More recently, published reports have begun to appear in which amyloid...
|
William E. Klunk
|
S20-S36
|
|
|
|
The potential of functional MRI as a biomarker in early Alzheimer's disease
Abstract: Functional magnetic resonance imaging (fMRI) is a relative newcomer in the field of biomarkers for Alzheimer's disease (AD). fMRI has several potential advantages, particularly for clinical ...
|
Reisa Sperling
|
S37-S43
|
|
|
|
Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments
10 October 2011
Abstract: Alzheimer's disease (AD) is associated with characteristic and progressive reductions in flourodeoxyglucose positron emission tomography (FDG PET) measurements of the regional cerebral metab...
|
Eric M. Reiman,
Alzheimer's Disease Biomarkers Working Group for the Alliance for Aging Research
|
S44-S47
|
|
|
|
Alliance for Aging Research AD Biomarkers Work Group: structural MRI
Abstract: Biomarkers of Alzheimer's disease (AD) are increasingly important. All modern AD therapeutic trials employ AD biomarkers in some capacity. In addition, AD biomarkers are an essential compone...
|
Clifford R. Jack
|
S48-S57
|
|
| Cognitive |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Changes in cognition
Abstract: The clinical hallmark of Alzheimer's disease (AD) is a gradual decline in cognitive function. For the majority of patients the initial symptom is an impairment in episodic memory, i.e., the ...
|
Marilyn S. Albert
|
S58-S63
|
|
| Use of biomarkers to expedite clinical trials |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Clinical trial methodologies for disease-modifying therapeutic approaches
10 October 2011
Abstract: In recent years, advances in Alzheimer's disease (AD) biomarker research have provided powerful tools to improve trial design. In particular, biomarkers provide powerful methods for the sele...
|
Paul S. Aisen
|
S64-S66
|
|
